Zanubrutinib (generic name: Zanubrutinib Capsules) is a prescription anti-tumor drug primarily indicated for the treatment of specific types of lymphoma. Pursuant to the laws and regulations of the People's Republic of China, this medication is only available with a doctor’s prescription, and patients must use it strictly in accordance with medical advice. Relevant information and authorized access channels are outlined below:
Prescription Status and Prerequisites for Purchase
As a targeted therapeutic agent, zanubrutinib may only be prescribed following a condition assessment by a qualified physician and is not available for over-the-counter purchase or self-administration.
Patients must first consult the Department of Oncology or Hematology at a Grade II Class A or higher-level hospital, where a physician will determine the drug’s suitability based on diagnostic findings.
Authorized Purchase Channels
Hospital Pharmacies
Zanubrutinib is available for purchase with a valid prescription at most large general hospitals and specialized cancer hospitals.
Licensed Offline Pharmacies
Select pharmacies holding prescription drug sales qualifications stock the medication, requiring patients to present the original paper prescription.
Authorized Online Platforms
State-certified internet hospital platforms offer online consultations followed by purchase with an electronic prescription, with drugs delivered via partner pharmacies.
Medication Precautions
Dosage adjustments or treatment discontinuation must be performed under full medical supervision throughout the treatment course. Regular follow-up tests, including complete blood count and liver/kidney function assessments, are mandatory.
Store the drug in a light-protected environment below 30°C and keep the container sealed after opening.
Adverse reactions such as infection or bleeding may occur during treatment; patients must contact their attending physician immediately if such symptoms develop.
Pricing and Medical Insurance Policy
Zanubrutinib has been included in the medical insurance formularies of several provinces and cities in China, with reimbursement rates varying by regional policy. For detailed information, patients are advised to consult their treating hospital or local medical insurance authority.
In regions where the drug is not covered by insurance, patients may inquire about patient assistance programs launched by the pharmaceutical company, some of which provide subsidies for medication purchases.
For further details on administration or drug procurement, patients are strongly recommended to complete diagnosis and treatment through formal medical institutions. Purchases from unofficial channels should be avoided to eliminate risks of counterfeit or substandard medications.
